Efficacy and Safety of a Novel Endothelin Receptor Antagonist, Macitentan, in Japanese Patients With Pulmonary Arterial Hypertension
| Autor: | Keiichi Fukuda, Yasuki Kihara, Masakazu Matsushita, Tohru Minamino, Hiroaki Dobashi, Satoshi Ikeda, Shuji Joho, Nobuhiro Tahara, Hidehiro Yamada, Shigetake Sasayama, Takeshi Kimura, Norifumi Nakanishi, Masanori Funauchi, Satoshi Sakai, Hiroshi Watanabe, Yukio Ozaki, Masaru Hatano, Takahisa Kondo, Koichiro Yoshioka, Nobuhiro Tanabe, Tsutomu Saji |
|---|---|
| Rok vydání: | 2016 |
| Předmět: |
Adult
Endothelin Receptor Antagonists Male medicine.medical_specialty medicine.drug_class Hypertension Pulmonary Hemodynamics Pulmonary Artery 030204 cardiovascular system & hematology 03 medical and health sciences chemistry.chemical_compound 0302 clinical medicine Asian People Internal medicine Clinical endpoint Natriuretic peptide Humans Medicine 030212 general & internal medicine Aged Macitentan Aged 80 and over Sulfonamides business.industry Endothelin receptor antagonist General Medicine Middle Aged medicine.disease Pulmonary hypertension Clinical trial Pyrimidines Treatment Outcome medicine.anatomical_structure chemistry Exercise Test Cardiology Vascular resistance Female Vascular Resistance Patient Safety Cardiology and Cardiovascular Medicine business |
| Zdroj: | Circulation Journal. 80:1478-1483 |
| ISSN: | 1347-4820 1346-9843 |
| DOI: | 10.1253/circj.cj-15-1305 |
| Popis: | BACKGROUND Macitentan is a novel, dual endothelin receptor antagonist with sustained receptor binding, used for the long-term treatment of pulmonary arterial hypertension (PAH). In the present study, we assessed the efficacy and safety of macitentan in Japanese patients with PAH. METHODS AND RESULTS Macitentan was administered at a once-daily dose of 10 mg in 30 patients. The primary endpoint was change in pulmonary vascular resistance (PVR) from baseline to week 24. Change to week 24 in the other hemodynamic parameters, 6-min walk distance (6MWD), World Health Organization (WHO) functional class, and plasmaN-terminal pro-brain natriuretic peptide (NT-pro-BNP), as well as time to clinical deterioration up to week 52 were also assessed as secondary endpoints. In the 28 patients on per-protocol analysis, PVR decreased from 667±293 to 417±214 dyn·sec·cm(-5)(P |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|